Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
By Jim Kling. November 7th 2024. Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to target the BCR-ABL fusion in chronic myelogenous leukemia. FDA Grants Orphan …
Perioperative Pembrolizumab Betters Survival in Stage III/IV Head …
Oct 8, 2024 · Perioperative pembrolizumab (Keytruda) led to improved event-free survival (EFS) in patients with stage III or IVA, resected head and neck squamous cell carcinoma (HNSCC), meeting the primary end point of the phase 3 KEYNOTE-689 study (NCT03765918). 1 “These results are substantial, as KEYNOTE-689 marks the first positive trial in 2 decades for patients with resected, locally advanced head ...
Talazoparib/Enzalutamide Combo Offers Significant Survival …
Oct 10, 2024 · The PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi), an androgen receptor pathway inhibitor (ARPI), led to statistically significant and meaningful improvements in overall survival (OS) in all-comers as well as patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), according to data from the phase 3 TALAPRO-2 ...
GLP-1 Agonists Poised to Impact Breast Cancer Care
Sep 25, 2024 · Recent trends have brought GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), to front of mind when discussing general weight loss. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, multiple presentations focused on the weight loss aspect of GLP-1 agonists for patients with breast cancer.
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
Dec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...
Challenges Facing Cancer Survivors
Oct 10, 2024 · Cancer survivors often face a unique set of challenges that can impact their physical, emotional, and social well-being. Some of the most common challenges include physical like fatigue or pain, emotional, social, and financial. These challenges can vary significantly from patient to patient, and not all survivors will experience all of them.
Targeting STK11 Mutations in Cancer - Targeted Oncology
Jan 29, 2022 · David R. Gandara, MD. STK11 mutation recently have become a biomarker and potential target of interest, especially for patients with lung cancer. Recent trials explore drugs like bemcentinib, everolimus, talazoparib, and others for potential approaches to …
Docetaxel Continues to Show Profound Benefits in Prostate Cancer
Jan 14, 2017 · In the larger STAMPEDE trial (2962 patients), adding docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naïve advanced prostate cancer. The median overall survival (OS) was 81 months with docetaxel plus standard of care (hormonal therapy with or without radiotherapy) versus 71 months ...
FDA Grants Zongertinib Breakthrough Therapy Designation in …
Aug 27, 2024 · Zongertinib (BI 1810631), an investigational oral therapy, was granted breakthrough therapy designation (BTD) from the FDA. China’s Center for Drug Evaluation (CDE) also granted a BTD for this agent in adult patients with advanced, unresectable or metastatic non–small cell lung cancer (NSCLC) whose tumors have activating HER2 mutations and who have received prior systemic therapy.
Dendritic Cell Vaccine Offers New Path in Pancreatic Cancer …
Jul 27, 2024 · A phase 1/2 study investigating a novel dendritic cell-based immunotherapy in patients with resected pancreatic cancer met its primary end point of a 2-year relapse-free survival (RFS) rate of at least 60%, signaling the promise of this treatment course in this difficult-to-treat cancer. 1 Of 28 patients with pancreatic cancer who completed the …